HER2 Breast Cancer
HER2 Breast Cancer
Advertisement
Leah LawrenceHER2 Breast Cancer | March 31, 2025
The FDA approved trastuzumab deruxtecan for HR-positive/HER2-low metastatic breast cancer based on DESTINY-Breast06 results.
Leah LawrenceHER2 Breast Cancer | March 31, 2025
The FDA granted Fast Track status to emiltatug ledadotin for advanced breast cancer following phase 1 results targeting B7-H4
Jordana JampelHER2 Breast Cancer | March 25, 2025
TILs can serve as a biomarker to identify patients with ERBB2-positive early breast cancer who can reduce adjuvant therapy.
Aliya OmerHER2 Breast Cancer | March 25, 2025
Aliya Omer, AstraZeneca, talks about data that backs the efficacy of olaparib in treating high-risk early breast cancer.
Rob DillardHER2 Breast Cancer | March 25, 2025
In patients with high-risk HER2-psoitive breast cancer, adjuvant trastuzumab emtansine reduces the long-term risk of death.
Jordana JampelHER2 Breast Cancer | March 25, 2025
The CDK4/6 inhibitor showed meaningful improvement in HR+, HER+ disease.
Rob DillardTriple-Negative Breast Cancer | March 25, 2025
New research suggests ICI therapy improves efficacy outcomes in early-stage breast cancer over adjuvant therapy.
Rob DillardHER2 Breast Cancer | March 25, 2025
 A year of treatment with the antibody-drug conjugate trastuzumab emtansine effectively prevents HER2-positive BC ...
Nera Lopetegui-Lia, MDHER2 Breast Cancer | March 31, 2025
Dr. Lopetegui-Lia reacts to Dr. Gatti-Mays' breast cancer panel discussion from Advancements in Oncology.
Dr. Margaret Gatti-MaysHER2 Breast Cancer | March 31, 2025
Dr. Margaret Gatti-Mays delves into the topic of HER2 tumor expression in breast cancer.
Rob DillardHER2 Breast Cancer | March 31, 2025
Dr. Margaret Gatti-Mays talks with The Oncology Brothers about the right treatments for endocrine-resistant breast cancer.
Rob DillardHER2 Breast Cancer | March 25, 2025
Eribulin is noninferior to trastuzumab and pertuzumab plus taxane in treating HER2-positive breast cancer.
Rob DillardHER2 Breast Cancer | March 25, 2025
The HER2DX ERBB2 mRNA score was significantly associated with improved survival in patients with metastatic HER2+ BC.
Rob DillardHER2 Breast Cancer | March 25, 2025
Using the HER2DX genomic tool is feasible in a real-world setting of patients with early-stage HER2-positive breast cancer.
Dr. Timothy YapHER2 Breast Cancer | March 26, 2025
Dr. Timothy Yap discusses the PETRA trial, which showed the efficacy of saruparib in treating HER2-negative breast cancer.
Rob DillardHER2 Breast Cancer | March 25, 2025
CNS radiotherapy with pyrotinib and capecitabine improves CNS progression in breast cancer patients with brain metastases.
Patrick DalyHER2 Breast Cancer | March 25, 2025
In a recent study, published in JAMA Oncology, researchers evaluated whether the HER2DX assay could predict ...
Patrick DalyHER2 Breast Cancer | March 25, 2025
Researchers of a study, published in Radiotherapy and Oncology, evaluated the effects of post-mastectomy radiation ...
Advertisement